Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Dec 5, 2025; 16(4): 110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Published online Dec 5, 2025. doi: 10.4292/wjgpt.v16.i4.110273
Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center
Michael Colwill, Jessica Padley, Umang Qazi, Sonia Mehta, Fiona Donovan, Ana Margarida Alves, Richard Pollok, Kamal Patel, Patrick Dawson, Sailish Honap, Andrew Poullis, Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, London SW17 0QT, United Kingdom
Michael Colwill, Richard Pollok, Andrew Poullis, Institute of Infection and Immunity, City St George's, University of London, London SW17 0RE, United Kingdom
Sailish Honap, School of Immunology and Microbial Sciences, King's College London, London WC2R 2LS, United Kingdom
Author contributions: Colwill M, Padley J, Qazi U contributed to investigation, writing-original draft, review and editing; Colwill M contributed to conceptualization; Colwill M, Padley J, Qazi M, Mehta S, Donovan F, Alves AM contributed to investigation; Pollok R, Patel K, Dawson P, Honap S, Poullis S contributed to writing-review and editing.
Institutional review board statement: This study was performed as a retrospective audit of real-world practice using anonymised data and therefore informed consent was not required from participants. As per local and NHS guidance, as this was a retrospective audit of real-world clinical practice, Research Ethics Committee approval and Institutional Review Board review was not required.
Informed consent statement: This study was performed as a retrospective audit of real-world practice using anonymised data and therefore informed consent was not required from participants. As per local and NHS guidance, as this was a retrospective audit of real-world clinical practice, Research Ethics Committee approval and informed consent forms was not required.
Conflict-of-interest statement: Colwill M served as a speaker and an advisory board member of or has received grants from Pfizer, Celltrion, Ferring, and Dr. Falk. Padley J, Qazi U, Alves AM, Pollok R, Poullis A report no relevant conflicts of interest for this article. Patel K has received honoraria for educational meetings and speaker fees from Abbvie, Janssen, Takeda, Dr. Falk Pharma, PredictImmune, Pfizer, and Ferring and has received advisory board fees from Abbvie, Galapagos, Pfizer, and Janssen. He has also received a grant from Abbvie to support research. Honap S served as a speaker, a consultant, and an advisory board member or has received grants from Pfizer, Janssen, AbbVie, Takeda, Alfasigma, Ferring, Lilly, Pharmacosmos, and Banook Group.
Data sharing statement: No additional data is available. For reasonable requests, data can be obtained from michael.colwill@nhs.net.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michael Colwill, MRCP, Department of Gastroenterology, St George's University Hospitals NHS Foundation Trust, Blackshaw Road, London SW17 0QT United Kingdom. michael.colwill@stgeorges.nhs.uk
Received: June 3, 2025
Revised: July 1, 2025
Accepted: September 5, 2025
Published online: December 5, 2025
Processing time: 185 Days and 16.1 Hours
Revised: July 1, 2025
Accepted: September 5, 2025
Published online: December 5, 2025
Processing time: 185 Days and 16.1 Hours
Core Tip
Core Tip: Despite evidence of superiority of risankizumab over ustekinumab when managing Crohn’s disease, it is unknown if switching from ustekinumab to risankizumab is effective. This retrospective study evaluated outcomes in 51 adults who switched from ustekinumab to risankizumab. Significant reductions in Harvey-Bradshaw Index scores were observed at all timepoints, with remission rates rising from 37.1% to 94.4% over 9 months. Albumin, C-reactive protein and calprotectin also improved. Patients with secondary loss of response to ustekinumab responded better than primary non-responders. No serious adverse events occurred. These findings support risankizumab as a safe, effective option after ustekinumab failure in refractory Crohn’s.